Wafik S. El-Deiry: NIH is a good opportunity to breath some life into innovation and US Biomedical Research
Wafik S. El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, shared a post on LinkedIn:
“My personal opinion is that reform of NIH is needed but with a dose of “do no harm.”
Major biomedical funder NIH poised for massive reform under Trump 2.0.
Sweeping changes and more research scrutiny could be on the way for the US National Institutes of Health.”
Quoting another post:
“I should add that if Donald Trump, Elon Musk and RFK, Jr. want to fix some things, the National Institutes of Health is a good opportunity to breath some life into innovation and US biomedical research.
The way to do that is to invest in science and medicine (maybe it’s time to double the budget as was last done in 1998, but with lessons learned), to understand and fix what has happened to life expectancy here, and to ensure the US rescues and maintains global leadership in STEM.”
Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023